US 7771729
Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
granted A61KA61K2039/5256A61K2039/53
Quick answer
US patent 7771729 (Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/5256, A61K2039/53, A61K2039/54, A61K2039/545